Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
To determine the feasibility and performance of sentinel lymph-node (SLN) mapping among women with high-risk endometrial cancer (EC).
Ninety-eight patients at high-risk EC were enrolled in this retrospective surgical trial from August 2016 to August 2018. All patients underwent intraoperative SLN biopsy, with ICG injection for laparoscopic staging; this was followed by pelvic and paraaortic lymphadenectomy (LAD). Outcomes included SLN detection rate, false-negative SLN algorithm rate, and the negative predictive value (NPV) of the SLN algorithm. The Chi-square test was used to analyze the relationship between SLN mapping and the risk factors. Then, we performed Kappa consistency check (P < 0.05 with Meaning), to estimate the consistency of SLN and lymph-node metastasis.
Successful biopsy occurred in 94 patients (170 sides) among 98 patients (196 sides). At least 1 SLN was identified in 86.7% (170/196). Overall, the false-negative rate (FNR) was 11.8% (2/17), NPV was 97.3% (72/74), and sensitivity was 88.2% (15/17). 22/98 patients (22.4%) with high-risk EC had at least one metastatic lymph node identified. When the SLN algorithm was retrospectively applied, the FNR was 9.1% (2/22) and sensitivity was 90.9% (20/22). Considering the surgeon’s experience, 68 cases of EC (except for 30 patients), the detection rate was 89.7% (122/136), NPV was 98.1% (50/51), and the FNR was 5.6% (1/18). The factor significantly affecting the detection rate of SLNs was lymphovascular space invasion (LVSI) (P = 0.016). SLN metastasis of EC was associated with depth of myometrial invasion (P = 0.034). The analysis result of SLN and the consistency of pelvic lymph-node metastasis status. As detected by Kappa coefficient was 0.939 (P < 0.001), suggests highly consistency.
Our SLN detection rate for high-risk EC was the same as previously reported. When SLN is not detected, better after 30 patients’ experience, is a reasonable alternative to complete LAD in high-risk EC. In addition, SLN shows high co-occurrence with pelvic lymph nodes. Therefore, SLN biopsy can be used to diagnose high-risk EC.
Papadia A, Imboden S, Siegenthaler F, Gasparri ML, Mohr S, Lanz S et al (2016) Laparoscopic indocyanine green sentinel lymph node mapping in endometrial cancer. Ann Surg Oncol 23(7):2206–2211 CrossRef
Bodurtha Smith AJ, Fader AN, Tanner EJ (2017) Sentinel lymph node assessment in endometrial cancer: a systematic review and meta-analysis. Am J Obstet Gynecol 216(5):459–476 CrossRef
Soliman PT, Westin SN, Dioun S, Sun CC, Euscher E, Munsell MF et al (2017) A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. Gynecol Oncol 146(2):234 CrossRef
Cormier B, Rozenholc AT, Gotlieb W, Plante M, Giede C (2015) Sentinel lymph node procedure in endometrial cancer: a systematic review and proposal for standardization of future research. Gynecol Oncol 138(2):478–485 CrossRef
Lheureux S, Oza AM (2016) Endometrial cancer-targeted therapies myth or reality? Review of current targeted treatments. Eur J Cancer 59:99–108 CrossRef
Buda A, Crivellaro C, Elisei F, Martino GD, Guerra L (2016) Impact of indocyanine green for sentinel lymph node mapping in early stage endometrial and cervical cancer: comparison with conventional radiotracer 99mTc and/or blue dye. Ann Surg Oncol 23(7):2183–2191 CrossRef
Buda A, Di MG, Vecchione F, Bussi B, Dell'Anna T, Palazzi S et al (2015) Optimizing strategies for sentinel lymph node mapping in early-stage cervical and endometrial cancer: comparison of real-time fluorescence with indocyanine green and methylene blue. Int J Gynecol Cancer 25(8):1513–1518 CrossRef
Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J et al (2016) ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Int J Gynecol Cancer 26(1):2–30 CrossRef
Ahmed M, Purushotham AD, Douek M (2014) Novel techniques for sentinel lymph node biopsy in breast cancer: a systematic review. Lancet Oncol 15(8):e351–e362 CrossRef
Burke TW, Levenback C, Tornos C, Morris M, Wharton JT, Gershenson DM (1996) Intraabdominal lymphatic mapping to direct selective pelvic and paraaortic lymphadenectomy in women with high-risk endometrial cancer: results of a pilot study. Gynecol Oncol 62(2):169–173 CrossRef
Sharma C, Deutsch I, Lewin SN, Burke WM, Qiao Y, Sun X et al (2011) Lymphadenectomy influences the utilization of adjuvant radiation treatment for endometrial cancer. Am J Obstet Gynecol 205(6):562.e1–562.e9 CrossRef
Lin H, Ding Z, Kota VG, Zhang X, Zhou J (2017) Sentinel lymph node mapping in endometrial cancer: a systematic review and meta-analysis. Oncotarget 8(28):46601–46610
Ruiz R, Gorostidi M, Jaunarena I, Goiri C, Aguerre J, Lekuona A (2018) Sentinel node biopsy in endometrial cancer with dual cervical and fundal indocyanine green injection. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc 28(1):139 CrossRef
Hagen B, Valla M, Aune G, Ravlo M, Abusland AB, Araya E et al (2016) Indocyanine green fluorescence imaging of lymph nodes during robotic-assisted laparoscopic operation for endometrial cancer: a prospective validation study using a sentinel lymph node surgical algorithm. Gynecol Oncol 143(3):479 CrossRef
Lopez Labrousse MI, Frumovitz M, Guadalupe Patrono M, Ramirez PT (2017) Sentinel lymph node mapping in minimally invasive surgery: role of imaging with color-segmented fluorescence (csf). Gynecol Oncol 146(3):676–677 CrossRef
Ehrisman J, Secord AA, Berchuck A, Lee PS, Santo ND, Lopezacevedo M et al (2016) Performance of sentinel lymph node biopsy in high-risk endometrial cancer. Gynecol Oncol Rep 17:69–71 CrossRef
Geppert B, Lönnerfors C, Bollino M, Arechvo A, Persson J (2017) A study on uterine lymphatic anatomy for standardization of pelvic sentinel lymph node detection in endometrial cancer. Gynecol Oncol 145(2):256–261 CrossRef
Persson J, Geppert B, Lönnerfors C, Bollino M, Måsbäck A (2017) Description of a reproducible anatomically based surgical algorithm for detection of pelvic sentinel lymph nodes in endometrial cancer. Gynecol Oncol 147(1):120–125 CrossRef
Rossi EC, Kowalski LD, Scalici J, Cantrell L, Schuler K, Hanna RK et al (2017) A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (fires trial). Obstet Gynecol Surv 72(8):479–480 CrossRef
Holloway RW, Abu-Rustum NR, Backes FJ, Boggess JF, Gotlieb WH, Jeffrey LW et al (2017) Sentinel lymph node mapping and staging in endometrial cancer: a society of gynecologic oncology literature review with consensus recommendations. Gynecol Oncol 146(2):405–415 CrossRef
Ahrendt GM, Laud P, Tjoe J, Eastwood D, Walker AP, Otterson MF et al (2002) Does breast tumor location influence success of sentinel lymph node biopsy? J Am Coll Surg 194(3):278–284 CrossRef
Lloyd LR, Wesen CA, Mccallum S (2002) An analysis of filtration and volume of radionucleotide in sentinel lymph node biopsy in breast cancer patients. Am Surg 68(4):373–375
- A retrospective validation study of sentinel lymph node mapping for high-risk endometrial cancer
- Springer Berlin Heidelberg
Archives of Gynecology and Obstetrics
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
Neu im Fachgebiet Gynäkologie und Geburtshilfe
Meistgelesene Bücher aus dem Fachgebiet
e.Med Kampagnen-Visual, Mail Icon II